• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Renal Cell Carcinoma Epidemiology and Patient Flow Analysis - 2012 Product Image

Global Renal Cell Carcinoma Epidemiology and Patient Flow Analysis - 2012

  • Published: October 2012
  • 24 pages
  • Fore Pharma

Fore Pharma announced the results of its Renal Cell Carcinoma patient population study in a new report ‘Global Renal Cell Carcinoma Epidemiology and Patient Flow Analysis - 2012’. The report provides insights into Renal Cell Carcinoma epidemiology, Renal Cell Carcinoma diagnosed patients, and Renal Cell Carcinoma treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Renal Cell Carcinoma derived from epidemiological analysis, percentage of patients diagnosed with Renal Cell Carcinoma, and percentage of patients treated with Renal Cell Carcinoma therapy.

The study helps executives estimate Renal Cell Carcinoma market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Renal Cell Carcinoma prevalence, Renal Cell Carcinoma diagnosis rate, and Renal Cell Carcinoma treatment rate for the period 2012-2019. The information is presented by leading READ MORE >

1. Renal Cell Carcinoma: Disease Definition
2. Global Renal Cell Carcinoma Patient Flow
2A. Global Renal Cell Carcinoma Prevalence
2B. Global Renal Cell Carcinoma Diagnosed Patients
2C. Global Renal Cell Carcinoma Treated Patients
3. Renal Cell Carcinoma Patient Flow in the US
3A. Renal Cell Carcinoma Prevalence in the US
3B. Renal Cell Carcinoma Diagnosed Patients in the US
3C. Renal Cell Carcinoma Treated Patients in the US
4. Renal Cell Carcinoma Patient Flow in Europe
4A. Renal Cell Carcinoma Prevalence in Europe
4B. Renal Cell Carcinoma Diagnosed Patients in Europe
4C. Renal Cell Carcinoma Treated Patients in Europe
5. Renal Cell Carcinoma Patient Flow in Germany
5A. Renal Cell Carcinoma Prevalence in Germany
5B. Renal Cell Carcinoma Diagnosed Patients in Germany
5C. Renal Cell Carcinoma Treated Patients in Germany
6. Renal Cell Carcinoma Patient Flow in France
6A. Renal Cell Carcinoma Prevalence in France
6B. Renal Cell Carcinoma Diagnosed Patients in France
6C. Renal Cell Carcinoma Treated Patients in France
7. Renal Cell Carcinoma Patient Flow in Spain
7A. Renal Cell Carcinoma Prevalence in Spain
7B. Renal Cell Carcinoma Diagnosed Patients in Spain
7C. Renal Cell Carcinoma Treated Patients in Spain
8. Renal Cell Carcinoma Patient Flow in Italy
8A. Renal Cell Carcinoma Prevalence in Italy
8B. Renal Cell Carcinoma Diagnosed Patients in Italy
8C. Renal Cell Carcinoma Treated Patients in Italy
9. Renal Cell Carcinoma Patient Flow in UK
9A. Renal Cell Carcinoma Prevalence in UK
9B. Renal Cell Carcinoma Diagnosed Patients in UK
9C. Renal Cell Carcinoma Treated Patients in UK
10. Renal Cell Carcinoma Patient Flow in Japan
10A. Renal Cell Carcinoma Prevalence in Japan
10B. Renal Cell Carcinoma Diagnosed Patients in Japan
10C. Renal Cell Carcinoma Treated Patients in Japan
11. Appendix
12. Research Methodology
12A. Sources

Table 1: Global Renal Cell Carcinoma Patient Flow (2012)
Table 2: Global Renal Cell Carcinoma Patient Flow Forecast (2012-2019)
Table 3: Renal Cell Carcinoma Patient Flow in the US (2012)
Table 4: Renal Cell Carcinoma Patient Flow Forecast in the US (2012-2019)
Table 5: Renal Cell Carcinoma Patient Flow in Europe (2012)
Table 6: Renal Cell Carcinoma Patient Flow Forecast in Europe (2012-2019)
Table 7: Renal Cell Carcinoma Patient Flow in Germany (2012)
Table 8: Renal Cell Carcinoma Patient Flow Forecast in Germany (2012-2019)
Table 9: Renal Cell Carcinoma Patient Flow in France (2012)
Table 10: Renal Cell Carcinoma Patient Flow Forecast in France (2012-2019)
Table 11: Renal Cell Carcinoma Patient Flow in Spain (2012)
Table 12: Renal Cell Carcinoma Patient Flow Forecast in Spain (2012-2019)
Table 13: Renal Cell Carcinoma Patient Flow in Italy (2012)
Table 14: Renal Cell Carcinoma Patient Flow Forecast in Italy (2012-2019)
Table 15: Renal Cell Carcinoma Patient Flow in UK (2012)
Table 16: Renal Cell Carcinoma Patient Flow Forecast in UK (2012-2019)
Table 17: Renal Cell Carcinoma Patient Flow in Japan (2012)
Table 18: Renal Cell Carcinoma Patient Flow Forecast in Japan (2012-2019)

Figure 1: Global Renal Cell Carcinoma Patient Flow (2012)
Figure 2: Global Renal Cell Carcinoma Patient Flow Forecast (2012-2019)
Figure 3: Renal Cell Carcinoma Patient Flow in the US (2012)
Figure 4: Renal Cell Carcinoma Patient Flow Forecast in the US (2012-2019)
Figure 5: Renal Cell Carcinoma Patient Flow in Europe (2012)
Figure 6: Renal Cell Carcinoma Patient Flow Forecast in Europe (2012-2019)
Figure 7: Renal Cell Carcinoma Patient Flow in Germany (2012)
Figure 8: Renal Cell Carcinoma Patient Flow Forecast in Germany (2012-2019)
Figure 9: Renal Cell Carcinoma Patient Flow in France (2012)
Figure 10: Renal Cell Carcinoma Patient Flow Forecast in France (2012-2019)
Figure 11: Renal Cell Carcinoma Patient Flow in Spain (2012)
Figure 12: Renal Cell Carcinoma Patient Flow Forecast in Spain (2012-2019)
Figure 13: Renal Cell Carcinoma Patient Flow in Italy (2012)
Figure 14: Renal Cell Carcinoma Patient Flow Forecast in Italy (2012-2019)
Figure 15: Renal Cell Carcinoma Patient Flow in UK (2012)
Figure 16: Renal Cell Carcinoma Patient Flow Forecast in UK (2012-2019)
Figure 17: Renal Cell Carcinoma Patient Flow in Japan (2012)
Figure 18: Renal Cell Carcinoma Patient Flow Forecast in Japan (2012-2019)

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Hard Copy A printed copy of the report will be shipped to you.
CD ROM The report will be shipped to you in CD ROM format. This is a single user license, allowing one specific user access to the product.
Site License The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos